GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elbit Imaging Ltd (OTCPK:EMITF) » Definitions » Debt-to-EBITDA

Elbit Imaging (Elbit Imaging) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Elbit Imaging Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Elbit Imaging's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Elbit Imaging's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Elbit Imaging's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.08 Mil. Elbit Imaging's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Elbit Imaging's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Elbit Imaging was 14.61. The lowest was -49.97. And the median was 1.70.

EMITF's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.21
* Ranked among companies with meaningful Debt-to-EBITDA only.

Elbit Imaging Debt-to-EBITDA Historical Data

The historical data trend for Elbit Imaging's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elbit Imaging Debt-to-EBITDA Chart

Elbit Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.79 - - - -

Elbit Imaging Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elbit Imaging's Debt-to-EBITDA

For the Medical Devices subindustry, Elbit Imaging's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elbit Imaging's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elbit Imaging's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Elbit Imaging's Debt-to-EBITDA falls into.



Elbit Imaging Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Elbit Imaging's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.525
=0.00

Elbit Imaging's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.078
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Elbit Imaging  (OTCPK:EMITF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Elbit Imaging Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Elbit Imaging's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Elbit Imaging (Elbit Imaging) Business Description

Traded in Other Exchanges
Address
3 Shimshon Street, Olympia A Tower, Petach Tikva, ISR, 4900102
Elbit Imaging Ltd is an Israel based company. The business activity of the group is operated through two segments including Medical industries and devices, and Plots in India. Geographically the business presence is in the region of America, Europe, and ROW. The company derives maximum revenue from the Medical industries and devices segment which operates in the field of life science that includes development, production, and marketing of treatment-oriented medical systems, and for certain cancer diseases in the America region.